Concepedia

E Colajori

EC

Statistics

Publications

4

Citations

1.1K

H-Index

4

Active since

1997

Affiliations

Weston Park Cancer Centre(Current)

E Colajori is an author at Weston Park Cancer Centre specializing in medicine, oncology, and pharmacology.

Publications per year

1997–2007

4

Publications

4

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

R. Charles Coombes, CF Snowdon, Robert Paridaens et al. · The Lancet · 2007 · 909 citations

Medicine, Endocrinology, Oncology +4

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer

G Brufman, E Colajori, N. Ghilezan et al. · Annals of Oncology · 1997 · 79 citations · Full text

Medicine, Oncology, Pharmacology +15

Dose-Intensive Epirubicin-Based Chemotherapy Is Superior to an Intensive Intravenous Cyclophosphamide, Methotrexate, and Fluorouracil Regimen in Metastatic Breast Cancer: A Randomized Multinational Study

Stephen P. Ackland, Antonio Antón, G. P. Breitbach et al. · Journal of Clinical Oncology · 2001 · 57 citations

Medicine, Oncology, Pharmacology +17

Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation

Donatella Moneta, Cristina Geroni, Olga Valota et al. · European Journal of Cancer · 2003 · 11 citations

Medicine, Pharmacology, Pharmacotherapy +12

1–4 of 4